Winrevair access in India: the CDSCO Rule 36 named-patient pathway
How adults in India with pulmonary arterial hypertension legally obtain Winrevair (sotatercept-csrk) from US-source supply through CDSCO personal importation, with validated cold-chain logistics and PAH-center coordination built into the case plan.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Winrevair in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Winrevair (sotatercept-csrk) is a first-in-class activin signaling inhibitor approved by the US FDA on 26 March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity and improve WHO functional class. In October 2025 the FDA updated the label, based on the Phase 3 ZENITH study, to include reduction of the risk of clinical worsening events including hospitalization for PAH, lung transplantation, and death. It is administered as a subcutaneous injection every three weeks as add-on to background PAH therapy. Indian commercial stocking and routine reimbursement of Winrevair lag US and EU availability, and PAH patients at Indian expert centres reach the medicine through the Central Drugs Standard Control Organization (CDSCO) personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, with Form 12A application and Form 12B permit issued by the Drugs Controller General of India (DCGI). Reserve Meds coordinates the supply through a US-licensed pharmaceutical wholesale partner from Accredo or CVS Specialty under DSCSA serialization, the validated 2 to 8 degree Celsius cold-chain logistics, and the documentation kit your PAH specialist needs to file.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
Why patients in India need Winrevair via the named-patient pathway
India's PAH clinical infrastructure has matured. Treating physicians at these centres routinely prescribe combinations of endothelin receptor antagonists, PDE-5 inhibitors or guanylate cyclase stimulators, and prostacyclin-pathway agents as background therapy. What is missing for many patients is a routinely stocked first-in-class activin-pathway inhibitor as an add-on option.
Three structural patterns drive the access gap for Winrevair specifically. First, registration timing: outside the US and EU, Winrevair is at an earlier stage in many Asian and Middle Eastern jurisdictions, with local approval, importation licensing, and routine commercial stocking lagging. Second, limited US specialty distribution: Merck has named Accredo Specialty Pharmacy and CVS Specialty as the two designated US dispensing channels, which means there is no broad retail or wholesale presence and inventory visibility outside those channels is limited. Third, PAH urgency: patients remaining symptomatic, functionally limited, or at elevated risk despite standard combination regimens are the population for whom add-on Winrevair changes the trajectory. The ZENITH data update extended the indication to include clinical-worsening reduction. The clinical case for timely access is not academic. The Rule 36 framework is the legal route, and routine cases at expert PAH centres move quickly when documentation is complete.
The CDSCO Rule 36 named-patient pathway for Winrevair
The legal foundation for personal import of an unregistered medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits the import of a small quantity of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit. Form 12B is the permit itself, issued by the office of the DCGI at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported is capped at one hundred average doses per application, which for Winrevair's every-three-week dosing covers a substantial supply window per filing.
For institutional Compassionate Use of drugs not approved for marketing in India at all, the parallel pathway is the Compassionate Use application route to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. This route applies when the drug is approved by a recognised reference authority (FDA, EMA, MHRA, Health Canada, PMDA) for a life-threatening condition, a serious permanent disability, or an unmet medical need. PAH WHO Group 1 fits that framing on the unmet-need axis.
For Winrevair specifically, the clinical-justification angle is precise. The strongest Form 12A applications consistently document: a pulmonologist-confirmed or cardiologist-confirmed diagnosis of pulmonary arterial hypertension WHO Group 1 with right-heart catheterisation hemodynamics, vasoreactivity status where measured, and the current WHO functional class; the patient's current background PAH regimen (endothelin receptor antagonist, PDE-5 inhibitor or guanylate cyclase stimulator, prostacyclin-pathway agent as applicable) with documented continuing symptoms or risk-stratification justifying add-on therapy; the proposed Winrevair dosing plan starting at 0.3 mg/kg subcutaneous every three weeks with planned escalation to the 0.7 mg/kg target maintenance dose if tolerated; and the pre-dose monitoring plan for hemoglobin and platelet count thresholds per the FDA label. CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing, and first-time or complex imports can take longer. We give you a written timeline estimate for your case before you commit. Indian families and PAH centres plan for a two to four week window from specialist decision to first injection, with the elapsed time dominated by upstream documentation assembly and downstream cold-chain logistics rather than the regulator's stamp.
Where Winrevair gets dispensed in India
Winrevair is supplied as a kit containing the lyophilised drug vial (45 mg or 60 mg), a pre-filled syringe of sterile water for injection as diluent, and supplies for subcutaneous administration. Storage class is refrigerated cold chain at 2 to 8 degree Celsius in the original carton, protected from light. After reconstitution to a final concentration of 50 mg/mL the product should be used as soon as possible and no later than four hours after reconstitution. After healthcare-professional training on reconstitution and subcutaneous injection technique, eligible patients or caregivers may self-administer Winrevair at home; the first doses are typically given under clinical supervision.
For patients in smaller cities without a dedicated PAH programme, the practical pattern is to route the case to a tertiary centre with an in-house import pharmacy for the initial dose escalation and monitoring, or to work through a CDSCO-licensed specialty importer in Mumbai, Delhi, or Bangalore that handles the Form 12A filing for a home-administration patient.
Real cost picture for Winrevair in India
Medicine price: quote on request. You get a written quote for your case before you commit.
India's Union Budget 2026-27 expanded customs-duty exemption on a set of named life-saving and rare-disease drugs; the specific HSN code and exemption status of each Winrevair shipment is confirmed at the documentation stage. GST on most life-saving medicines is 5 percent.
None of the major Indian private insurers reimburse a Rule 36 personal import as a standard line item. The PAH category attracts insurer interest because it is a chronic, progressive, life-limiting condition with a defined specialist pathway, and several plans have considered case-by-case reimbursement when the underlying medicine is on their formulary and the import route is a stocking workaround. Reserve Meds itemises US-side procurement, international cold-chain logistics, and coordination separately on every firm quote to give the insurer or the hospital a clean documentation record to evaluate against. Cash-pay is the operating default.
Typical timeline for Winrevair in India
We give you a written timeline estimate for your case before you commit. Because Winrevair is dosed every three weeks on an indefinite chronic basis, Reserve Meds plans repeat-shipment cadence at case acceptance and quotes patients for an initial sourcing window with the understanding that ongoing access is re-quoted as treatment continues.
What your physician needs to provide
The clinical justification letter is the cornerstone of the Form 12A filing. For Winrevair, the strongest letters consistently include: a PAH specialist's confirmed diagnosis of pulmonary arterial hypertension WHO Group 1 with right-heart catheterisation hemodynamics (mean pulmonary artery pressure, pulmonary vascular resistance, pulmonary capillary wedge pressure), vasoreactivity status, and current WHO functional class; the patient's documented current background PAH regimen with dates and dose; the rationale for adding an activin-pathway inhibitor (continuing symptoms despite combination background therapy, intermediate or high risk on standard risk-stratification scores, or recurrent clinical-worsening events); the proposed dosing plan starting at 0.3 mg/kg subcutaneous every three weeks with planned escalation to the 0.7 mg/kg target maintenance dose if tolerated; the pre-dose monitoring plan for hemoglobin and platelet count with label-defined thresholds for dose interruption, reduction, or discontinuation; and the prescribing physician's NMC registration number. The dispensing facility's drug licence, the chain-of-custody plan from the US specialty pharmacy to the Indian PAH centre, and the patient identifier complete the file.
The treating PAH specialist retains the clinical decision and the Pharmacovigilance Programme of India (PvPI) adverse-event reporting obligation through the Indian Pharmacopoeia Commission. Reserve Meds includes the PvPI reference in the physician documentation kit; the reporting obligation itself stays with the prescribing physician.
Common questions about Winrevair in India
Will a private insurer cover Winrevair?
Each plan handles named-patient imports case by case. None of the major Indian private insurers reimburse a Rule 36 personal import of an unregistered specialty biologic as a standard line item. Some plans have considered reimbursement on a case basis where the patient meets PAH-specialist criteria and the import route is a documented stocking workaround. Reserve Meds provides the itemised documentation that lets the insurer evaluate. Cash-pay is the operating default.
Will my CGHS or ESIC entitlement cover Winrevair?
CGHS provides for life-saving and anti-cancer medicines that are not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS), case by case. Drugs not approved by the DCGI for use in India face a stricter Expert Committee review. ESIC's formulary is narrower. Neither scheme is structured for routine personal-import reimbursement of an activin-pathway inhibitor for PAH. Check eligibility with your CGHS Wellness Centre before assuming coverage.
What is the safety profile we should be aware of?
Adverse events reported more frequently with Winrevair than placebo in the STELLAR trial included epistaxis, telangiectasia, dizziness, increased hemoglobin, thrombocytopenia, and increased blood pressure. Injection-site reactions are also documented. The full safety profile, warnings, and precautions are in the FDA label. Hemoglobin and platelet counts are assessed before each dose, with label-defined thresholds for dose interruption or modification.
Can the patient self-administer at home in India?
After training by a healthcare professional on reconstitution and subcutaneous injection technique, eligible patients or caregivers may self-administer. The first doses are typically given under clinical supervision at the PAH centre. Reserve Meds confirms training capacity at the dispensing institution as part of intake; cold-chain integrity from the patient's refrigerator to the injection site is part of the patient-education kit.
Is there a competitor or alternative?
Winrevair is the only approved drug in its mechanistic class (activin signaling inhibition) for PAH. Other PAH therapies (endothelin receptor antagonists, PDE-5 inhibitors, guanylate cyclase stimulators, prostacyclin-pathway agents) operate via different mechanisms and are typically continued as background therapy alongside Winrevair rather than replaced by it. The choice to add Winrevair is a treating-clinician decision made on patient-specific factors. Reserve Meds does not make therapeutic substitution recommendations.
What is the typical course duration?
Treatment is chronic and indefinite as long as the patient benefits and tolerates therapy. There is no defined finite course. Reserve Meds plans repeat-shipment cadence at case acceptance to align with the every-three-week dosing schedule.
Where Reserve Meds fits in Winrevair cases
Reserve Meds is a US-based digital health company. We do not replace your PAH specialist, do not replace CDSCO or the DCGI, and do not replace the dispensing PAH centre or the licensed specialty importer. What we do is orchestrate the supply through a US-licensed pharmaceutical wholesale partner from Accredo or CVS Specialty under DSCSA serialization with full pedigree, validated 2 to 8 degree Celsius cold-chain logistics with temperature monitoring through to handoff, and the documentation kit your PAH specialist needs for the Form 12A filing. Standard NPP coordination applies with particular attention to cold-chain integrity across multi-leg international transit, destination-centre training capacity for subcutaneous self-administration, and CBC monitoring discipline before each dose. A single point of contact carries the case from intake through the every-three-week dose cycle.
Next step
If an Indian adult with WHO Group 1 PAH on background combination therapy has a PAH specialist considering add-on Winrevair, start your case at the portal. We will respond within one business day with a documentation kit for your specialist and a written quote.
Reserved for you.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Indian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.